medicines with anti-cholinergic properties have a significant adverse effect on cognitive and physical function , but limited evidence exists for delirium or mortality outcomes
OBJECTIVES to determine the effect of drugs with anti-cholinergic properties on relevant health outcomes .
Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg
Objectives : To assess the cognitive effects of single doses of solifenacin 10 mg compared with placebo ( primary objective ) and oxybutynin immediate release ( IR ) 10 mg ( secondary objective ) in elderly subjects . Methods : Single-centre , r and omised , double-blind , placebo-controlled study in 12 healthy elderly volunteers , with three crossover periods separated by two 14-day washout periods . Each sequence consisted of a single dose of solifenacin 10 mg in one period , oxybutynin IR 10 mg in another and placebo in another . Aspects of attention , information processing , working memory , episodic memory and self-rated mood and alertness were tested using the vali date d Cognitive Drug Research computerised assessment system . Results : There was no evidence from absolute mean values or changes from baseline to suggest that solifenacin 10 mg impaired cognition or self-ratings of mood and alertness versus placebo . Post-hoc ANCOVA showed no statistically significant cognitive deterioration with solifenacin versus placebo , when measured at a time point closest to the probable Cmax of solifenacin . Oxybutynin was associated with statistically significant impairments in several measures of cognitive function at a time point corresponding with its probable Cmax . Conclusion : In this pilot study , single 10 mg doses of solifenacin did not show any clear propensity to impair cognitive function in a healthy elderly population
medicines with anti-cholinergic properties have a significant adverse effect on cognitive and physical function , but limited evidence exists for delirium or mortality outcomes
OBJECTIVES to determine the effect of drugs with anti-cholinergic properties on relevant health outcomes .